Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2025-08-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于控股子公司收到化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding its controlling subsidiary receiving an approval notice for the listing application of a chemical raw material drug. It contains no financial statements or detailed financial data, but rather regulatory approval information and a risk warning. The document is short (766 characters) and serves as a formal notification to investors about a regulatory approval event. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2025-08-25 Chinese
金陵药业股份有限公司关于分公司收到药品再注册批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the receipt of a drug re-registration approval notice from the Fujian Provincial Drug Administration. It details the approval of a specific drug for re-registration and mentions the impact and risk related to this approval. The document is short (734 characters) and serves as an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-20 Chinese
金陵药业股份有限公司关于南京新工医疗产业投资基金合伙企业（有限合伙）拟清算注销暨关联交易的进展公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the progress of the liquidation and deregistration of an investment fund related to the company, including regulatory approvals and impact statements. It is a regulatory update about a corporate action (liquidation of a fund and related transactions) rather than a financial report, earnings release, or management discussion. The document is relatively short (816 characters) and serves as a formal public disclosure of a corporate event. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-08-15 Chinese
金陵药业股份有限公司章程（2025年8月）
Governance Information Classification · 100% confidence The document is the articles of association (章程) of Jinling Pharmaceutical Company Limited, detailing the company's organizational structure, shareholder rights, board and management roles, shareholder meeting procedures, and other governance matters. It includes extensive provisions on shareholder meetings, voting rights, board responsibilities, and internal governance rules. There is no indication that this is an annual report, financial statement, earnings release, or any other financial or regulatory filing. Instead, it is a governance document that sets out the company's internal rules and governance practices. Therefore, the appropriate classification is Governance Information (CGR). The document length and detail confirm it is the full governance charter, not just an announcement or summary.
2025-08-08 Chinese
江苏泰和律师事务所关于金陵药业股份有限公司2025年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the procedural legality and validity of a company's 2025 second extraordinary shareholders' meeting. It details the convening, attendance, voting procedures, and results of the meeting. It does not contain financial statements or performance data but focuses on the legality and validity of the shareholders' meeting and its resolutions. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, not an annual report, earnings release, or other financial report. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is under 5,000 characters, but it is not merely an announcement or certification; it is a substantive legal opinion letter.
2025-08-08 Chinese
金陵药业股份有限公司关于回购注销部分限制性股票减少注册资本暨通知债权人的公告20250805
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Jinling Pharmaceutical Co., Ltd. regarding the repurchase and cancellation of restricted shares, which leads to a reduction in registered capital. It includes details about the number of shares repurchased, prices, total amount, and the resulting decrease in share capital. It also notifies creditors about their rights in relation to this capital reduction, referencing relevant company law. The document is a formal announcement about a share repurchase and capital change event, not a full financial report or earnings release. It is not a report publication or certification. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is short (1720 characters), consistent with an announcement rather than a full report.
2025-08-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.